Please select the option that best describes you:
Topics:
Medical Oncology • Cancer Prevention • Internal Medicine • Diabetes • Gastroenterology • Endocrinology • Obesity Medicine
How do you counsel patients on semaglutide or tirzepatide in light of potential cancer risks?
Do you avoid using these agents only in patients with history of medullary thyroid cancer or pancreatic cancer? Are there other cancer risks we should discuss with patients prior to initiation?
Answer from: at Community Practice
Use of GLP 1 RAs has sky-rocketed in recent years due to what seems to be a positive class effect on T2DM, weight loss, renal outcomes, cardiac outcomes and hepatic outcomes. I am not aware of any signals of increased malignancy risk. A brief literature review found meta-analyses showing possible be...
Sign in or Register to read more